The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis

References

• Raghu G, Collard HR, Egan JJ, et al. Committee on idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
   Web of Science ®Google Scholar
• Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2:566–572.
   Web of Science ®Google Scholar
• Van Manen MJ, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25:278–286.
   PubMed Web of Science ®Google Scholar
• Yount SE, Beaumont JL, Chen SY, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung. 2016;194:227–234.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265–275.
   PubMed Web of Science ®Google Scholar
• Cottin V. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev. 2013;22:153–157.
   PubMedGoogle Scholar
• Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46:186–196.
   PubMed Web of Science ®Google Scholar
• Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113–1130.
   Web of Science ®Google Scholar
• Bonella F, Kreuter M, Hagmeyer L, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration. 2016;92:98–106.
   PubMed Web of Science ®Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Cottin V, Kreuter M, et al. IPF, comorbidities and management implications. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(Suppl 1):17–23.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. OFEV (nintedanib) Summary of Product Characteristics [internet]; 2017, Jan [cited 2017 Apr 10]. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474.pdf
   Google Scholar
• Boehringer Ingelheim. OFEV (nintedanib) Prescribing Information [internet]; 2017, Feb [cited 2017 Apr 10]. Available from: docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ofev/ofev.pdf
   Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–19.
   Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782.
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:157.
   PubMed Web of Science ®Google Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.
   PubMed Web of Science ®Google Scholar
• Ackermann M, Kim YO, Wagner WL, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis. 2017 Mar 10. [Epub ahead of print]. doi:10.1007/s10456-017-9543-z
   PubMed Web of Science ®Google Scholar
• Tandon K, Herrmann FE, Ayaub E, et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. Abstract accepted for presentation at: American Thoracic Society International Conference; 2017 19–24 May; Washington, DC, USA.
   Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. (Link to Creative Commons license. 2015;16:116. Available: https://creativecommons.org/licenses/by/4.0/).
   PubMed Web of Science ®Google Scholar
• Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193:178–185.
   Web of Science ®Google Scholar
• Cottin V, Taniguchi H, Richeldi L, et al. Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS trials. Poster presented at: the International Colloquium on Lung and Airway Fibrosis; 2014 Sept 20–24; Mont Tremblant, Quebec, Canada.
   Google Scholar
• Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340–346.
   PubMed Web of Science ®Google Scholar
• Maher TM, Flaherty KR, Noble PW, et al. Effect of baseline FVC on lung function decline with nintedanib in patients with IPF. Eur Respir J. 2015;46(Suppl. 59):OA4499.
   Google Scholar
• Raghu G, Crestani B, Bailes Z, et al. Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J. 2015;46(Suppl 59):OA4502.
   Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Selman M, Kirsten A-M, et al. Long-term efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: results from the TOMORROW trial and its open-label extension. Poster presented at: 19th International Colloquium on Lung and Airway Fibrosis (ICLAF); 2016 Sept 24–28; Dublin, Ireland.
   Google Scholar
• Crestani B, Ogura T, Pelling K, et al. Long-term treatment with nintedanib in patients with idiopathic pulmonary fibrosis: an update from INPULSIS®-ON. Paper presented at: European Respiratory Society (ERS) International Congress; 2016 Sept 3–7; London, UK.
   Google Scholar
• Wuyts WA, Kolb M, Stowasser S, et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung. 2016;194:739–743.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Inoue Y, et al. Effect of dose reductions, treatment interruptions and dose intensity on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the INPULSIS® trials. Poster presented at: Pulmonary Fibrosis Foundation (PFF) Summit; 2015 Nov 12–14; Washington, DC, USA.
   Google Scholar
• Crestani B, Kolb M, Wallaert B, et al. Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (IPF) irrespective of dose: subgroup analysis of INPULSIS-ON. Abstract accepted for presentation at: American Thoracic Society International Conference; 2017 19–24 May; Washington, DC, USA.
   Google Scholar
• Fletcher SV, Jones MG, Renzoni E, et al. Nintedanib for the treatment of idiopathic pulmonary fibrosis – initial clinical experience in a UK cohort. Thorax. 2015;70:A78.
   Web of Science ®Google Scholar
• Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5(9):E78.
   PubMed Web of Science ®Google Scholar
• Noth I, Allinger A, Kaul M, et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the United States. Qjm. 2016;109(suppl 1):S51–2.
   PubMed Web of Science ®Google Scholar
• Pereira C, Baddini-Martinez JA, Guedes Baldi B, et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil. Poster presented at: Congresso Sociedade Brasileira de Pneumologia e Tisiologia (SBPT) [Congress of the Brazilian Society of Pneumology and Physiology]; 2016 Oct 11–15; Brazil.
   Google Scholar
• Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017 Mar 20. [Epub ahead of print]. doi:10.1111/resp.13024
   PubMed Web of Science ®Google Scholar
• Milger K, Kneidinger N, Neurohr C, et al. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J. 2015;46:1217–1221.
   PubMed Web of Science ®Google Scholar
• Hirsh V, Blais N, Burkes R, et al. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol. 2014;21:329–336.
   PubMed Web of Science ®Google Scholar
• Keefe D, Bowen J, Gibson R, et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011;16:432–444.
   PubMed Web of Science ®Google Scholar
• Delanote I, Wuyts WA, Yserbyt J, et al. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med. 2016;16:156.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15:829–835.
   PubMedGoogle Scholar
• Mortimer KM, Bartels D, Capapey J, et al. Characterizing idiopathic pulmonary fibrosis patients using US health plan claims data. Sarcoidosis Vasc Diffuse Lung Dis. in press.
   Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382–1392.
   PubMed Web of Science ®Google Scholar